Baoshan R. Cao

Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study.

Journal: Advances in therapy

Published: May 15, 2026

Tumor Microenvironment-Responsive Antibody Fragment-Cleavable PEGylated Drug Conjugates (AFCDC) for Improved Tumor Penetration and Antitumor Efficacy.

Journal: Journal of medicinal chemistry

Published: April 29, 2026

Chemically Masked aPD-L1-Sialidase Conjugate for Tumor-Specific Desialylation and Immunotherapy.

Journal: Angewandte Chemie (International ed. in English)

Published: February 26, 2026

Circulating tumor DNA as a predictive biomarker for prognosis in hepatocellular carcinoma: a systematic review and meta-analysis.

Journal: Journal of the National Cancer Center

Published: December 08, 2025

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.

Journal: Nature communications

Published: November 17, 2025

Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer  with HER2 Mutation

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: October 29, 2025

Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review.

Journal: Discover oncology

Published: October 02, 2025

Harnessing Tumor Organoids to Revolutionize Immunotherapy Research.

Journal: Cancer medicine

Published: September 10, 2025

Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 22, 2025

Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan-Tumor.

Journal: Cancer innovation

Published: August 12, 2025

Predictive Value of Patient-Derived Tumor Cell Cluster-Based Drug Sensitivity Assay in Advanced NSCLC.

Journal: Clinical Medicine Insights. Oncology

Published: August 09, 2025

Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.

Journal: Translational lung cancer research

Published: August 09, 2025

Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study.

Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study.

Tumor Microenvironment-Responsive Antibody Fragment-Cleavable PEGylated Drug Conjugates (AFCDC) for Improved Tumor Penetration and Antitumor Efficacy.

Tumor Microenvironment-Responsive Antibody Fragment-Cleavable PEGylated Drug Conjugates (AFCDC) for Improved Tumor Penetration and Antitumor Efficacy.

Chemically Masked aPD-L1-Sialidase Conjugate for Tumor-Specific Desialylation and Immunotherapy.

Chemically Masked aPD-L1-Sialidase Conjugate for Tumor-Specific Desialylation and Immunotherapy.

Circulating tumor DNA as a predictive biomarker for prognosis in hepatocellular carcinoma: a systematic review and meta-analysis.

Circulating tumor DNA as a predictive biomarker for prognosis in hepatocellular carcinoma: a systematic review and meta-analysis.

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.

Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer with HER2 Mutation

Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer with HER2 Mutation

Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review.

Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review.

Harnessing Tumor Organoids to Revolutionize Immunotherapy Research.

Harnessing Tumor Organoids to Revolutionize Immunotherapy Research.

Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study.

Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study.

Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan-Tumor.

Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan-Tumor.

Predictive Value of Patient-Derived Tumor Cell Cluster-Based Drug Sensitivity Assay in Advanced NSCLC.

Predictive Value of Patient-Derived Tumor Cell Cluster-Based Drug Sensitivity Assay in Advanced NSCLC.

Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.

Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.

Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer  with HER2 Mutation

Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer  with HER2 Mutation